Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Checkpoint inhibitor therapy benefits advanced bladder cancer patients

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.06.16
Views: 2614

Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA

Dr Balar meets with ecancertv at ASCO 2016 to discuss a phase II trial with atezolizumab, an antibody targeting PD-L1, and its use against bladder cancer. 

Reporting from the IMvigor210 trial, Dr Balar explains that, with many affected too frail to receive cisplatin, advanced bladder cancer patients on carboplatin-based regimens can expect a survival of nine to ten months, compared to the median survival of 14.8 months.

More about these results can be seen in his press conference here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation